Pre-Submission Review for Cardiovascular Research: What Circulation and JACC Reviewers Expect

Current cardiovascular journal instructions and reporting standards point to the same practical checklist. A review should ask whether the manuscript can satisfy a clinician, a statistical reader, and the target journal's first-screen editor at the same time.

Circulation, JACC, European Heart Journal, and Cardiovascular Research all expose parts of this standard in public author guidance. The point is not that every journal uses the same box. The point is that a cardiovascular paper is judged through endpoints, methods, and practice consequence before prose polish matters.

Statistical readers commonly check:

• sample size calculations and power analysis

• appropriateness of the primary analysis (intention-to-treat vs per-protocol)

• handling of missing data (multiple imputation, sensitivity analyses)

• multiplicity corrections for secondary endpoints and subgroup analyses

• time-to-event analysis methodology (Kaplan-Meier, Cox proportional hazards)

• competing risk analysis where applicable

• effect size reporting with confidence intervals

• Whether the primary endpoint matches the registration, protocol, and analysis plan.
• Whether time-to-event, competing-risk, missing-data, and multiplicity choices are defensible.
• Whether subgroup claims are pre-specified or clearly exploratory.
• Whether the Clinical Perspective, Central Illustration, or Research in Context language matches the evidence level.
• Whether adverse events, harms, and safety signals are visible rather than buried.
• Whether the target journal is the right cardiovascular lane: clinical practice, intervention, imaging, heart failure, electrophysiology, prevention, or mechanism.

Circulation requires a Clinical Perspective section with two questions answered in bulleted format:

"What Is New?" (maximum 100 words, 2 to 3 bullets) - What the paper adds to existing knowledge.

"What Are the Clinical Implications?" (maximum 100 words, 2 to 3 bullets) - How the findings affect clinical practice.

JACC requires a Central Illustration and its own significance framing. European Heart Journal and Cardiovascular Research use different article structures, but the underlying question is similar: what does this result change for cardiovascular readers?

These sections are not afterthoughts. Editors read them before deciding on triage. A weak Clinical Perspective signals that the clinical consequence is unclear, which is exactly what triggers desk rejection.

In Manusights reviews, cardiovascular manuscripts usually fail in one of three places. The endpoint hierarchy is less disciplined than the abstract suggests. The statistics section is technically correct but not robust enough for an independent statistical reviewer. Or the Clinical Perspective and framing language imply a practice consequence that the event counts, follow-up, or comparator do not yet justify.

Our review of current cardiovascular journal instructions points the same way. Editors are not only asking whether the result is interesting. They are asking whether the paper is already packaged in a way that a statistician, clinician, and editor can all trust on the first pass.

The recurring high-value fix is a one-page evidence ledger before submission: registered endpoint, analysis population, missing-data rule, main figure, adverse-event table, practice implication, and the exact limitation sentence that prevents overclaim.

Endpoint drift: the registry, methods, abstract, and first figure do not all point to the same primary endpoint. We check the manuscript, tables, trial record, statistical analysis plan, and limitations before the claim reaches an editor.

Subgroup overclaim: the discussion treats an exploratory subgroup, biomarker, imaging signal, or secondary endpoint like the main clinical result. We check the abstract, figures, statistics, data supplement, and cover letter for claim-evidence alignment.

Statistical-review exposure: the methods are readable but leave missing-data handling, multiplicity, competing-risk logic, or sensitivity analyses too hard to audit. We check the methods, supplement, code availability, data statement, and response-ready explanation.

Clinical-framing mismatch: the Clinical Perspective, Central Illustration, or Research in Context box says "practice-changing" before the event count, comparator, or follow-up can support it. We check the first page, figures, adverse-event table, and limitation language.

Wrong cardiovascular lane: a mechanistic paper is pitched to a practice journal, or a clinical dataset is pitched as mechanism. We check journal fit, references, cover letter, abstract, and likely reviewer pool before the submission fee and waiting period are spent.

The common thread is that cardiovascular editors rarely reject only "the writing." They reject a mismatch between the manuscript's strongest claim and the evidence an independent statistical or clinical reviewer can audit. That is why our pre-submission review keeps returning to the same surfaces: endpoint table, Kaplan-Meier curve, forest plot, adverse-event table, analysis-plan language, Clinical Perspective, Central Illustration, cover letter, and limitation paragraph. If those surfaces disagree, the paper feels unstable even when the science is promising.

For a cardiovascular author, the practical output should be specific enough to edit from: move this endpoint caveat into the abstract, downgrade this subgroup sentence, add this sensitivity analysis to the supplement, change this Clinical Perspective bullet, or retarget from a broad practice journal to a mechanistic or subspecialty lane. Without that level of manuscript-component instruction, "pre-submission review" becomes generic advice.

Method note: this page combines public author guidance from cardiovascular journals with ICMJE, CONSORT, STROBE, TRIPOD-AI, and EQUATOR reporting expectations. Those public field signals do not decide whether one manuscript is ready, but they define what a cardiovascular reviewer is likely to audit first.

Cardiovascular trials have some of the most rigorous reporting requirements in medicine:

• CONSORT 2025 compliance for randomized trials

• DSMB oversight documentation

• pre-specified stopping rules

• adjudicated clinical endpoints (not self-reported)

• appropriate comparators (not just placebo vs active when standard of care exists)

• STROBE discipline for observational studies and registry analyses

• STARD or TRIPOD-AI where diagnostic or prediction claims drive the manuscript

• CONSORT 2025 checklist complete with page references

• primary endpoint matches registration (ClinicalTrials.gov)

• DSMB charter and stopping rules described

• endpoints adjudicated by blinded committee

• appropriate comparator selected and justified

• patient-reported outcomes included

• long-term follow-up data or plan described

• cost-effectiveness or health economic data if applicable

• STROBE checklist complete

• confounding addressed systematically (propensity score, instrumental variables, or other approach)

• sensitivity analyses for unmeasured confounding

• temporal relationships established where causal claims are made

• large enough sample for the effect size claimed

• relevance to human cardiovascular disease explicitly stated

• multiple experimental models used

• in vivo validation of in vitro findings

• translational pathway described (mechanism to therapeutic target)

• appropriate heart failure models, arrhythmia models, or atherosclerosis models used

• Clinical Perspective box completed (Circulation format: 2 to 3 bullets for each question, 100 words each maximum)

• Central Illustration prepared (JACC)

• clinical implication stated concretely, not speculatively

• the finding represents a genuine change in clinical thinking or practice

The cardiovascular manuscript readiness check evaluates methodology, citation integrity, and journal fit. For cardiovascular manuscripts, citation verification is particularly important because the field publishes landmark trials frequently and missing a recent trial that changed practice signals an incomplete literature review.

The same check gives figure-level feedback, which matters for cardiovascular papers that rely on Kaplan-Meier curves, forest plots, central illustrations, CONSORT diagrams, and adverse-event tables to communicate results. Figure-text inconsistencies in these displays undermine credibility quickly.

For manuscripts targeting Circulation, JACC, European Heart Journal, or Cardiovascular Research, use the first pass to decide whether the problem is journal fit, evidence strength, reporting completeness, or clinical framing. Do that before buying editing or submitting to a reach journal.

Send the manuscript, target journal, abstract, cover letter if drafted, trial registration or protocol if relevant, statistical analysis plan, main figures, key supplements, reporting checklist, and any prior reviewer comments. If the paper is a registry, imaging, device, prediction, or translational study, include enough data and methods detail for the reviewer to assess the actual claim rather than only the prose.

A useful cardiovascular pre-submission review should deliver a submit, revise, retarget, or diagnose recommendation. It should name the top endpoint, statistics, clinical-framing, figure, citation, reporting-checklist, or journal-lane risk and tell the team what to fix before upload.

Use this page when the reader wants a discipline-specific readiness review before cardiovascular submission. Use how to avoid desk rejection when the reader wants general rejection-prevention workflow. Use a journal-specific submission guide when the reader needs portal mechanics, article types, or formatting. Use a cover-letter page when the problem is the letter rather than the manuscript evidence package.

Cardiovascular research spans basic physiology, translational science, clinical trials, and device engineering. Each journal in the field has a distinct editorial lens: EHJ wants European relevance, Circulation wants AHA-aligned clinical impact, JACC wants ACC-relevant practice evidence, and Circulation Research wants mechanistic cardiovascular science.

Submitting a strong cardiovascular paper to the wrong journal costs 2-4 months. The most common mismatch: sending mechanistic cardiovascular science to a clinical journal (EHJ, Circulation) when it belongs at Circulation Research, or sending a clinical trial to a basic science journal when it belongs at JACC or EHJ.

A cardiovascular manuscript readiness check identifies which cardiovascular journal fits your manuscript's editorial lens. The same scan verifies citations and scores readiness.

That distinction matters because cardiovascular journals often look similar from the outside while screening for very different things on the inside. A clean mechanistic story with limited clinical consequence may be strong science and still look misplaced at a practice-facing journal. A clinically important dataset with thin mechanistic work can have the opposite problem. Pre-submission review helps catch that mismatch before the wrong editorial team makes the decision for you.